Arctic Bioscience — Capital/Financing Update 2026

Apr 1, 2026

Arctic Bioscience - New long-term financing

Arctic Bioscience - New long-term financing

Arctic Bioscience has secured new long-term financing through a bank loan of NOK

15 million. Together with previously disclosed increase in credit facility of

NOK 8 million from December 2025, the company has increased available liquidity

by a total of NOK 23 million.

The new loan and the increased credit facility are secured through a growth

guarantee from Innovation Norway of NOK 6 million and through guarantees from

various shareholders of a total of NOK 18 million.

Regarding guarantees from shareholders:

Agreements have been entered into with shareholders who have provided guarantees

for the new financing. There will be no guarantee fee to be paid. The guarantors

shall, for the entire term of the loan agreement, have an irrevocable right to

redeem the entire outstanding amount of the loan on behalf of the company by

paying such amount directly to the bank, and to have the resulting claim against

the company converted into shares in the company. The claim is convertible by

the guarantors at any time into freely tradable shares. Conversion price per

share is the lower of 70% x previous 5 trading days VWAP (T+1) from the date the

conversion notice is sent, or maximum conversion price of the lower of NOK 3 or

70% x price-per-share in any equity financing in the period where the guarantee

is valid.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.